PeptideDB

Triphala

CAS: 857906-76-4 F: W:

Triphala, an Ayurvedic polyherbal formulation comprising of equiproportional fruit parts of Terminalia chebula, Terminal
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Triphala, an Ayurvedic polyherbal formulation comprising of equiproportional fruit parts of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica[1]. Triphala inhibits NF-κB activation. Triphala exerts antifungal action[2]. Anti-adipogenic, anti-inflammatory, and anti-neoplastic activities.
Invitro Triphala regulates adipogenesis through modulation of expression of adipogenic genes in 3T3-L1 cell line. Triphala significantly decreases the adipogenesis in 3T3-L1 cells by reducing lipid accumulation and inhibiting the expression of adipogenic genes. The 3T3-L1 cells treated with Triphala show ~1.43-, 1.67-, and 2.5-fold decreases in lipid content at 1, 10, and 100 μg/mL concentrations, respectively, compared to the cells treated with induction cocktail alone. Triphala regulates lipid accumulation by down regulating expression of adipogenic genes, resulting into prevention of adipogenesis[1].Triphala reduces expression of inflammatory mediators such as IL-17, COX-2, and RANKL through inhibition of NF-κB activation[2]. Triphala exerts antifungal action against Asperigillus species and has been reported to inhibit the fungus by up to 37.96% in vitro[2].
Name Triphala
CAS 857906-76-4
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Banjare J, et al. Triphala, Regulates Adipogenesis through Modulation of Expression of Adipogenic Genes in 3T3-L1 Cell Line. Pharmacogn Mag. 2018 Jan;13(Suppl 4):S834-S839. [2]. Peterson CT, et al. Therapeutic Uses of Triphala in Ayurvedic Medicine. J Altern Complement Med. 2017 Aug;23(8):607-614.